To the full analysis
Buyback calculator for City Therapeutics
City Therapeutics Stock: Key Metrics
CTYCity Therapeutics had an operating margin of 35.4% and a return on invested capital (ROIC) of 13.4% in fiscal 2019.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 20 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2005 | 76.3% | 9.8% | 9.7% |
| 2006 | 76.5% | 12.2% | 12.2% |
| 2007 | 78.4% | 24.1% | 15.1% |
| 2008 | 83.8% | 21.8% | 13.8% |
| 2009 | 84.5% | 26.3% | 12.3% |
| 2010 | 82.1% | 26.8% | 11.7% |
| 2011 | 72.4% | 18.1% | 8.2% |
| 2012 | 67.6% | 21.5% | 9.6% |
| 2013 | 68.1% | 23.7% | 11.0% |
| 2014 | 67.4% | 23.9% | 11.0% |
| 2015 | 68.0% | 25.2% | 12.0% |
| 2016 | 67.1% | 26.1% | 12.2% |
| 2017 | 66.3% | 27.1% | 19.4% |
| 2018 | 67.4% | 31.3% | 19.6% |
| 2019 | 70.1% | 35.4% | 22.4% |
Returns on Capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2005 | 41.8% | no data | −100.0% |
| 2006 | 69.5% | 8.2% | 8.1% |
| 2007 | 152.7% | 17.0% | 200.0% |
| 2008 | 183.0% | 17.0% | 200.0% |
| 2009 | 200.0% | 19.2% | 102.7% |
| 2010 | −100.0% | 19.6% | 200.0% |
| 2011 | 5.5% | 5.9% | 3.1% |
| 2012 | 8.5% | 6.5% | 5.1% |
| 2013 | 10.0% | 7.4% | 6.0% |
| 2014 | 10.6% | 7.6% | 4.3% |
| 2015 | 12.1% | 8.6% | 5.0% |
| 2016 | 12.5% | 8.9% | 5.1% |
| 2017 | 17.7% | 13.1% | 7.9% |
| 2018 | 16.9% | 12.6% | 8.1% |
| 2019 | 18.1% | 13.4% | 8.7% |
Data and Required Disclosures
- ; time horizon around 12 months
- Rated Neutral since 7 Nov 2026
- Price: closing price of 19 Nov 2026
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2019. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
